Chen D, Menon H, Verma V, et al. - In this phase 1/2, single-arm trial including 46 patients with unresectable locally advanced esophageal cancer, researchers assessed toxic influences, local control, and overall survival rates following chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease. Patients received chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose with concurrent docetaxel and capecitabine or fluorouracil. This treatment strategy provided promising local control rates, which were higher than rates reported in 97 similar patients who were treated with a standard 50.4-Gy dose of radiotherapy without a simultaneous integrated boost. Additionally, mild toxic effects were experienced, with no grade 4 to 5 adverse events. Overall, encouraging local control and good tolerability were reported in relation to treatment with chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose in patients with locally advanced esophageal cancer.